CTC BIO, INC. Logo

CTC BIO, INC.

Develops and manufactures human and animal health products using microbial fermentation.

060590 | KO

Overview

Corporate Details

ISIN(s):
KR7060590007
LEI:
Country:
South Korea
Address:
경기도 화성시 동탄첨단산업1로 27 금강펜테리움IX타워 A동 901호, 화성시

Description

CTC BIO, INC. is a company specializing in the development, manufacturing, and distribution of products for human and animal health. The company leverages core technologies in microbial fermentation and coating to create its product portfolio. Key business areas include human pharmaceuticals, functional foods, and a comprehensive range of animal health solutions. The animal health division offers veterinary medicines, such as antibiotics and coccidiostats, feed additives, and innovative bacteriophage-based products for disease control. In the human health sector, the company provides various pharmaceuticals and is recognized for its advanced manufacturing of probiotics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-09-03 00:00
주식등의대량보유상황보고서(일반)
Korean 82.3 KB
2025-09-01 00:00
주식등의대량보유상황보고서(일반)
Korean 89.9 KB
2025-08-12 00:00
[기재정정]사업보고서 (2024.12)
Korean 2.1 MB
2025-08-12 00:00
반기보고서 (2025.06)
Korean 1.7 MB
2025-07-25 00:00
단기차입금증가결정
Korean 8.9 KB
2025-05-14 00:00
분기보고서 (2025.03)
Korean 1.7 MB
2025-04-16 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB
2025-04-16 00:00
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.4 KB
2025-04-16 00:00
주식등의대량보유상황보고서(일반)
Korean 103.9 KB
2025-04-16 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-04-16 00:00
주식등의대량보유상황보고서(일반)
Korean 92.9 KB
2025-03-31 00:00
정기주주총회결과
Korean 18.6 KB
2025-03-21 00:00
감사보고서제출
Korean 25.0 KB
2025-03-21 00:00
사업보고서 (2024.12)
Korean 587.2 KB

Automate Your Workflow. Get a real-time feed of all CTC BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CTC BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CTC BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.